Traders should monitor APOLLO Phase 3 top-line results in Q4 2026 as the single most important binary catalyst — success would confirm the CRL-response path and likely drive a >8-15% rally for this early-stage biotech. The RALLY-MF data strengthen the DISC-0974 profile ahead of End-of-Phase 2 meetings, supporting a second pivotal program. DISC-3405 initial data in Q4 adds further optionality. The 75% T+20 win rate on prior IRON reports supports bullish positioning into this catalyst sequence.
Price Chart
Executive Summary
Disc Medicine announced updated Phase 2 data for DISC-0974 in myelofibrosis anemia (55% major response in non-transfusion-dependent patients, 64% transfusion independence in low-burden TD) and sustained bitopertin PPIX reductions in EPP at EHA 2026. The company confirmed a Type A meeting with FDA where APOLLO Phase 3 data, due Q4 2026, can serve as basis for a CRL response and potentially support traditional approval. Initial DISC-3405 data in polycythemia vera also expected Q4 2026.
Key Facts
- Phase 2 RALLY-MF: 55% of nTD patients achieved hemoglobin increase ≥1.5 g/dL for ≥12 weeks (major response)
- 64% of TD Low and 50% of TD High MF patients achieved transfusion independence over 12-16 weeks
- 56% of JAK inhibitor-concomitant patients achieved major hematologic response across transfusion groups
- HELIOS OLE: Sustained PPIX reductions and improved light tolerance with up to 2.5+ years bitopertin exposure
- Type A meeting confirmed APOLLO Phase 3 readout in Q4 2026 can serve as basis for CRL response and potentially support traditional approval
- RESTORE-PV Phase 2 initial data for DISC-3405 in polycythemia vera expected Q4 2026 — third program could enter pivotal development in 2027
- DISC-0974 well-tolerated; diarrhea was only related AE in ≥2 subjects, majority of AEs not related
Financial Impact
Disc Medicine has no revenue or earnings yet. The catalyst-rich H2 2026 hinges on APOLLO bitopertin Phase 3, which can potentially resolve the existing CRL and unlock a traditional approval for EPP (an orphan indication with no approved therapies) — value-driving for a $2.6B market cap biotech entirely dependent on pipeline success.
Risk Factors
- APOLLO Phase 3 failure would be severely bearish — bitopertin is the most advanced asset and a CRL is already outstanding; a miss could eliminate path-to-approval
- CRL on CMC or safety/efficacy grounds if APOLLO data are not clean + additional manufacturing/resolution risk before re-submission
- Clinical-stage biotech with no revenue — any pipeline setback (DISC-0974 regulatory delay, DISC-3405 early data miss) would erode premium valuation
- Broader biotech sentiment or financing risk — Disc may require equity raises to fund three programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311034 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $74.14 $69.18 | ▼ −6.69% | ▼ −6.19% | $64.48 (−13.03%) |
Sep 9, 2026 22d ago | Press Release | $74.14 $69.18 | ▼ −6.69% | ▼ −6.19% | $64.48 (−13.03%) |
Sep 3, 2026 28d ago | Insider Cluster | $79.23 $68.92 | ▲ +13.01% | ▲ +11.80% | $64.48 (+18.62%) |
Sep 2, 2026 29d ago | 144 | $79.37 $70.06 | ▼ −11.73% | ▼ −10.58% | $64.48 (−18.76%) |
Aug 27, 2026 5w ago | Insider Cluster | $82.55 $79.37 | ▼ −3.85% | ▼ −4.12% | $64.48 (−21.89%) |
Aug 18, 2026 6w ago | Insider Cluster | $80.32 $82.67 | ▲ +2.93% | ▲ +3.31% | $64.48 (−19.72%) |
Aug 14, 2026 6w ago | Insider Cluster | $80.05 $80.94 | ▲ +1.11% | ▲ +2.30% | $64.48 (−19.45%) |
Jul 30, 2026 9w ago | 8-K | $79.21 $77.44 | ▼ −2.23% | ▼ −5.86% | $64.48 (−18.60%) |
Jul 30, 2026 9w ago | Press Release | $79.21 $77.44 | ▼ −2.23% | ▼ −5.86% | $64.48 (−18.60%) |
Jul 14, 2026 11w ago | Insider Cluster | $76.02 $74.32 | ▼ −2.24% | ▼ −1.26% | $64.48 (−15.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access